Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Globe Newswire•02/10/2026•09:30 ET
0
Key Highlights
- ➤Budoprutug Phase 2 PrisMN data selected for oral presentation at ASN Kidney Week 2026
- ➤CLYM116 Phase 1 safety, tolerability, PK, and PD results to be presented
- ➤Budoprutug case study reports durable response in minimal change disease
- ➤Three presentations cover CLYM116 and budoprutug across immune-mediated kidney diseases
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio
Get started
Create a free account to read the full story.